Association of the arginine-16 polymorphism desensitization and β2-agonist intrinsic efficacy

2003 ◽  
Vol 111 (2) ◽  
pp. S304
Author(s):  
B.J. Lipworth ◽  
D.K.C. Lee ◽  
G.P. Currie ◽  
I.P. Hall ◽  
J.J. Lima
2007 ◽  
Vol 101 (5) ◽  
pp. 1007-1014 ◽  
Author(s):  
Nicola A. Hanania ◽  
Robert H. Moore ◽  
Janice L. Zimmerman ◽  
Charles T. Miller ◽  
Remzi Bag ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.


1999 ◽  
Vol 96 (3) ◽  
pp. 253 ◽  
Author(s):  
B.J. LIPWORTH ◽  
I.P. HALL ◽  
I. AZIZ ◽  
K.S. TAN ◽  
A. WHEATLEY

1999 ◽  
Vol 179 (4) ◽  
pp. 974-979 ◽  
Author(s):  
Akira Kaneko ◽  
Yngve Bergqvist ◽  
Miho Takechi ◽  
Morris Kalkoa ◽  
Osamu Kaneko ◽  
...  

2006 ◽  
Vol 43 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Sebastian Bonner ◽  
Thomas Matte ◽  
Mitchell Rubin ◽  
Joanne K. Fagan ◽  
Jennifer Ahern ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document